Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03063437 · ClinicalTrials.gov registry record · Phase 2
A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization
A Phase 2 study, sponsored by Microbiome Health Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03063437: Completed Phase 2 study, sponsored by Microbiome Health Research Institute.
NCT03063437 is a Phase 2 study that has completed, run by Microbiome Health Research Institute. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03063437, a Phase 2 study, has completed, sponsored by Microbiome Health Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The objective of this study is to provide preliminary insight into the safety and efficacy of fecal microbiota transplantation (FMT) for the eradication of gastrointestinal carriage of vancomycin-resistant Enterococcus.
Primary Outcome
VRE decolonization is defined by absence of VRE on stool culture using standard clinical laboratory techniques at Day 10 (± 3 days) after randomization.
Interventions
- BIOLOGICAL Encapsulated fecal microbiota preparation
- BIOLOGICAL Encapsulated placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-08-17 |
| Est. Completion | 2019-02-26 |
| Phase | Phase 2 |
What the finished NCT03063437 record still lists
NCT03063437 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Encapsulated fecal microbiota preparation is the first listed.
NCT03063437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03063437 about?
NCT03063437 is a clinical study titled "A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization". The objective of this study is to provide preliminary insight into the safety and efficacy of fecal microbiota transplantation (FMT) for the eradication of gastrointestinal carriage of vancomycin-resistant Enterococcus.
What is the current status of trial NCT03063437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-08-17. Estimated completion is 2019-02-26.
What interventions are being tested in trial NCT03063437?
The interventions under investigation include: Encapsulated fecal microbiota preparation (BIOLOGICAL), Encapsulated placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT03063437?
This trial is sponsored by Microbiome Health Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03063437's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI